Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Joseph Edelman. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Joseph Edelman har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Joseph Edelman. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ACRV / Acrivon Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-04-11 | ACRV | PERCEPTIVE ADVISORS LLC | 2.353.000 | 8,5000 | 2.353.000 | 8,5000 | 20.000.500 | 7 | 10.5400 | 4.800.120 | 24,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ACRV / Acrivon Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ADMA / ADMA Biologics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ADMA / ADMA Biologics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ALDX / Aldeyra Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ALDX / Aldeyra Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ANIP / ANI Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ANIP / ANI Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ATHA / Athira Pharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATHA / Athira Pharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ATXS / Astria Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATXS / Astria Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CRNX / Crinetics Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CRNX / Crinetics Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb FOLD / Amicus Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg FOLD / Amicus Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2016-08-25 | FOLD | PERCEPTIVE ADVISORS LLC | 1.100.000 | 6,8100 | 1.100.000 | 6,8100 | 7.491.000 | 119 | 4.53 | -2.508.000 | -33,48 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LPTX / Leap Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-06-22 | LPTX | PERCEPTIVE ADVISORS LLC | 1.750.000 | 2,0000 | 175.000 | 20,0000 | 3.500.000 | 240 | 301 | 49.175.000 | 1.405,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LPTX / Leap Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LYRA / Lyra Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LYRA / Lyra Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MGTX / MeiraGTx Holdings plc – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MGTX / MeiraGTx Holdings plc – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NAUT / Nautilus Biotechnology, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NAUT / Nautilus Biotechnology, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb OBIO / Orchestra BioMed Holdings, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-01 | OBIO | PERCEPTIVE ADVISORS LLC | 700.000 | 2,7500 | 700.000 | 2,7500 | 1.925.000 | 25 | 3.0000 | 175.000 | 9,09 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg OBIO / Orchestra BioMed Holdings, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SCYX / SCYNEXIS, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SCYX / SCYNEXIS, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SLDB / Solid Biosciences Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SLDB / Solid Biosciences Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SLNO / Soleno Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SLNO / Soleno Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TLPH / Talphera, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TLPH / Talphera, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VRCA / Verrica Pharmaceuticals Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VRCA / Verrica Pharmaceuticals Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VYNE / VYNE Therapeutics Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRV / Acrivon Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VYNE / VYNE Therapeutics Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRV / Acrivon Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Joseph Edelman som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-05 |
|
4 | OBIO |
Orchestra BioMed Holdings, Inc.
Common Stock |
P - Purchase | 700.000 | 5.292.556 | 15,24 | 2,75 | 1.925.000 | 14.554.529 | |
2025-05-01 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -298.886 | 3.104.139 | -8,78 | 1,34 | -400.507 | 4.159.546 | |
2025-05-01 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -437.881 | 3.403.025 | -11,40 | 1,41 | -617.412 | 4.798.265 | |
2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -250.000 | 3.840.906 | -6,11 | 1,41 | -352.500 | 5.415.677 | |
2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -215.283 | 4.090.906 | -5,00 | 1,56 | -335.841 | 6.381.813 | |
2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -1.054.669 | 4.306.189 | -19,67 | 1,95 | -2.056.605 | 8.397.069 | |
2025-04-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -3.400.000 | 5.875.851 | -36,65 | 1,42 | -4.828.000 | 8.343.708 | |
2025-02-21 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 5.000.000 | 11.833.539 | 73,17 | 4,03 | 20.150.000 | 47.689.162 | |
2025-02-14 |
|
4 | ADGM |
Adagio Medical Holdings, Inc.
Common Stock |
A - Award | 64.167 | 9.675.684 | 0,67 | ||||
2024-08-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1.250.000 | 12.531.103 | 11,08 | 4,00 | 5.000.000 | 50.124.412 | |
2024-08-01 | 3 | ADGM |
Adagio Medical Holdings, Inc.
Common stock |
7.160.397 | ||||||||
2024-07-17 | 3 | OBIO |
Orchestra BioMed Holdings, Inc.
Common Stock, $0.0001 par value per share |
4.592.556 | ||||||||
2024-04-15 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
P - Purchase | 2.353.000 | 5.360.858 | 78,23 | 8,50 | 20.000.500 | 45.567.293 | |
2024-04-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 37.712 | 9.275.851 | 0,41 | 4,74 | 178.755 | 43.967.534 | |
2024-04-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 140.281 | 9.238.139 | 1,54 | 4,67 | 655.112 | 43.142.109 | |
2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 309.847 | 9.097.858 | 3,53 | 4,09 | 1.267.274 | 37.210.239 | |
2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 186.051 | 8.788.011 | 2,16 | 3,44 | 640.015 | 30.230.758 | |
2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 8.374 | 8.601.960 | 0,10 | 3,25 | 27.216 | 27.956.370 | |
2024-02-21 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
G - Gift | -170.317 | 0 | -100,00 | ||||
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
F - Taxes | -19.218 | 17.082 | -52,94 | 4,76 | -91.478 | 81.310 | |
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
F - Taxes | -19.218 | 17.082 | -52,94 | 4,76 | -91.478 | 81.310 | |
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
M - Exercise | 36.300 | 36.300 | 2,52 | 91.476 | 91.476 | ||
2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
M - Exercise | 36.300 | 36.300 | 2,52 | 91.476 | 91.476 | ||
2024-02-05 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 2.481.350 | 4.873.721 | 103,72 | 12,09 | 29.999.522 | 58.923.287 | |
2024-01-12 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 3.410.713 | 6.833.539 | 99,65 | 5,53 | 18.861.243 | 37.789.471 | |
2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 163.954 | 5.402.964 | 3,13 | 2,38 | 390.211 | 12.859.054 | |
2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 409.598 | 5.239.010 | 8,48 | 2,44 | 999.419 | 12.783.184 | |
2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 32.134 | 4.829.412 | 0,67 | 2,28 | 73.266 | 11.011.059 | |
2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 115.774 | 7.099.182 | 1,66 | 7,24 | 838.204 | 51.398.078 | |
2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 126.116 | 6.983.408 | 1,84 | 7,08 | 892.901 | 49.442.529 | |
2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 79.726 | 6.857.292 | 1,18 | 7,20 | 574.027 | 49.372.502 | |
2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 54.652 | 6.777.566 | 0,81 | 6,49 | 354.691 | 43.986.403 | |
2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 250.000 | 6.722.914 | 3,86 | 6,67 | 1.667.500 | 44.841.836 | |
2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 200.000 | 6.472.914 | 3,19 | 6,17 | 1.234.000 | 39.937.879 | |
2023-12-22 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 740.000 | 2.392.371 | 44,78 | 6,20 | 4.588.000 | 14.832.700 | |
2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 277.008 | 6.272.914 | 4,62 | 5,36 | 1.484.763 | 33.622.819 | |
2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 456.923 | 5.995.906 | 8,25 | 5,41 | 2.471.953 | 32.437.851 | |
2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 500.000 | 5.538.983 | 9,92 | 5,97 | 2.985.000 | 33.067.729 | |
2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
P - Purchase | 333.333 | 333.333 | 15,00 | 4.999.995 | 4.999.995 | ||
2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
P - Purchase | 333.333 | 333.333 | 15,00 | 4.999.995 | 4.999.995 | ||
2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
C - Conversion | 2.579.502 | 2.579.502 | |||||
2023-10-18 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 460.546 | 1.611.699 | 40,01 | 6,51 | 2.999.997 | 10.498.607 | |
2023-10-18 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 614.062 | 1.652.371 | 59,14 | 6,51 | 4.000.000 | 10.763.545 | |
2023-10-18 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -306.499 | 8.593.586 | -3,44 | 1,74 | -533.308 | 14.952.840 | |
2023-10-18 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -2.450.000 | 8.900.085 | -21,59 | 1,60 | -3.920.000 | 14.240.136 | |
2023-10-17 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 876.808 | 10.794.876 | 8,84 | 22,81 | 19.999.990 | 246.231.122 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 250.000 | 3.074.542 | 8,85 | 20,00 | 5.000.000 | 61.490.840 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 36.939 | 2.824.542 | 1,33 | 21,00 | 775.719 | 59.315.382 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 117.996 | 2.787.603 | 4,42 | 20,03 | 2.363.460 | 55.835.688 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 88.685 | 2.669.607 | 3,44 | 19,11 | 1.694.770 | 51.016.190 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 52.691 | 2.580.922 | 2,08 | 18,24 | 961.084 | 47.076.017 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 75.477 | 2.528.231 | 3,08 | 17,28 | 1.304.243 | 43.687.832 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27.769 | 2.452.754 | 1,15 | 16,00 | 444.304 | 39.244.064 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 3.326 | 2.424.985 | 0,14 | 14,61 | 48.593 | 35.429.031 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 30.511 | 2.421.659 | 1,28 | 13,92 | 424.713 | 33.709.493 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 42.838 | 2.391.148 | 1,82 | 12,84 | 550.040 | 30.702.340 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 77.837 | 2.348.310 | 3,43 | 11,81 | 919.255 | 27.733.541 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 37.911 | 2.270.473 | 1,70 | 11,05 | 418.917 | 25.088.727 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 5.419 | 2.232.562 | 0,24 | 9,52 | 51.589 | 21.253.990 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 13.687 | 2.227.143 | 0,62 | 8,30 | 113.602 | 18.485.287 | |
2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 5.703 | 2.213.456 | 0,26 | 7,65 | 43.628 | 16.932.938 | |
2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 200 | 2.207.753 | 0,01 | 5,93 | 1.186 | 13.091.975 | |
2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 78.468 | 2.207.553 | 3,69 | 5,98 | 469.239 | 13.201.167 | |
2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 64.630 | 2.129.085 | 3,13 | 5,93 | 383.256 | 12.625.474 | |
2023-06-02 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 3.610.832 | 11.469.117 | 45,95 | 2,49 | 8.999.999 | 28.586.774 | |
2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 7.500 | 2.064.455 | 0,36 | 5,59 | 41.925 | 11.540.303 | |
2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 10.000 | 2.056.955 | 0,49 | 5,28 | 52.800 | 10.860.722 | |
2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 17.500 | 2.046.955 | 0,86 | 5,34 | 93.450 | 10.930.740 | |
2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 22.500 | 2.029.455 | 1,12 | 5,27 | 118.575 | 10.695.228 | |
2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 37.500 | 2.006.955 | 1,90 | 5,18 | 194.250 | 10.396.027 | |
2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 25.000 | 1.969.455 | 1,29 | 5,48 | 137.000 | 10.792.613 | |
2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27.500 | 1.944.455 | 1,43 | 5,45 | 149.875 | 10.597.280 | |
2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27.300 | 1.916.955 | 1,44 | 5,12 | 139.776 | 9.814.810 | |
2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 25.200 | 1.889.655 | 1,35 | 4,62 | 116.424 | 8.730.206 | |
2023-05-18 | 3 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
1.864.455 | ||||||||
2023-05-15 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 4.347.826 | 11.281.103 | 62,71 | 5,75 | 25.000.000 | 64.866.342 | |
2023-05-01 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
U - Other | -5.162.782 | 0 | -100,00 | 0,45 | -2.323.252 | ||
2023-04-25 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 133.742 | 5.162.782 | 2,66 | 0,45 | 60.184 | 2.323.252 | |
2023-04-25 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 39.506 | 5.029.040 | 0,79 | 0,45 | 17.778 | 2.263.068 | |
2023-04-25 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 70.200 | 4.989.534 | 1,43 | 0,45 | 31.450 | 2.235.311 | |
2023-04-20 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 56.000 | 4.919.334 | 1,15 | 0,45 | 25.200 | 2.213.700 | |
2023-04-20 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 137.000 | 4.863.334 | 2,90 | 0,45 | 61.376 | 2.178.774 | |
2023-04-20 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 15.800 | 4.726.334 | 0,34 | 0,45 | 7.078 | 2.117.398 | |
2023-04-17 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 4.800 | 4.710.534 | 0,10 | 0,45 | 2.160 | 2.119.740 | |
2023-04-17 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 11.500 | 4.705.734 | 0,24 | 0,45 | 5.175 | 2.117.580 | |
2023-04-17 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 140.134 | 4.694.234 | 3,08 | 0,45 | 63.060 | 2.112.405 | |
2023-04-13 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 129.000 | 4.554.100 | 2,92 | 0,44 | 56.760 | 2.003.804 | |
2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -4.251.563 | 41.440.729 | -9,30 | 0,11 | -467.672 | 4.558.480 | |
2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -1.832.563 | 45.691.816 | -3,86 | 0,13 | -238.233 | 5.939.936 | |
2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -4.810.623 | 47.524.379 | -9,19 | 0,16 | -769.700 | 7.603.901 | |
2023-04-06 | 3 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
3.672.662 | ||||||||
2023-04-06 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 339.000 | 4.425.100 | 8,30 | 0,44 | 149.160 | 1.947.044 | |
2023-04-06 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 217.500 | 4.086.100 | 5,62 | 0,45 | 97.875 | 1.838.745 | |
2023-04-06 |
|
4 | CEMI |
CHEMBIO DIAGNOSTICS, INC.
Common Stock |
P - Purchase | 195.938 | 3.868.600 | 5,34 | 0,44 | 86.213 | 1.702.184 | |
2022-12-21 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 908.265 | 1.038.309 | 698,43 | 11,01 | 9.999.998 | 11.431.782 | |
2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 73.107 | 73.107 | |||||
2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 365.536 | 3.422.826 | 11,96 | ||||
2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 2.163.120 | 3.057.290 | 241,91 | 7,05 | 15.249.996 | 21.553.894 | |
2022-11-18 | 3 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
3.007.858 | ||||||||
2022-11-02 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares, nil par value |
S - Sale | -8.255.607 | 7.945.211 | -50,96 | 0,08 | -660.449 | 635.617 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -406 | 1.939.723 | -0,02 | 22,79 | -9.253 | 44.206.287 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -178.726 | 1.940.129 | -8,44 | 22,01 | -3.933.759 | 42.702.239 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -7.240 | 2.118.855 | -0,34 | 23,23 | -168.185 | 49.221.002 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -89.979 | 2.126.095 | -4,06 | 22,26 | -2.002.933 | 47.326.875 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -5.415 | 2.216.074 | -0,24 | 24,78 | -134.184 | 54.914.314 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -38.310 | 2.221.489 | -1,70 | 24,18 | -926.336 | 53.715.604 | |
2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -100.340 | 2.259.799 | -4,25 | 23,23 | -2.330.898 | 52.495.131 | |
2022-08-22 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 998.240 | 3.728.491 | 36,56 | 2,40 | 2.395.776 | 8.948.378 | |
2022-08-18 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 1.425.000 | 6.511.727 | 28,01 | 35,00 | 49.875.000 | 227.910.445 | |
2022-08-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 15.000 | 11.350.085 | 0,13 | 7,85 | 117.750 | 89.098.167 | |
2022-08-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 100.000 | 11.335.085 | 0,89 | 7,50 | 750.000 | 85.013.138 | |
2022-08-10 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 97.000 | 11.235.085 | 0,87 | 7,24 | 702.280 | 81.342.015 | |
2022-08-09 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 141.000 | 11.138.085 | 1,28 | 6,95 | 979.950 | 77.409.691 | |
2022-08-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 95.100 | 10.997.085 | 0,87 | 6,17 | 586.767 | 67.852.014 | |
2022-08-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 100.000 | 10.901.985 | 0,93 | 5,84 | 584.000 | 63.667.592 | |
2022-08-04 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 412.406 | 10.801.985 | 3,97 | 5,59 | 2.305.350 | 60.383.096 | |
2022-08-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 144.185 | 10.389.579 | 1,41 | 5,05 | 728.134 | 52.467.374 | |
2022-08-02 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 222.123 | 10.245.394 | 2,22 | 5,03 | 1.117.279 | 51.534.332 | |
2022-08-01 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 119.392 | 10.023.271 | 1,21 | 5,00 | 596.960 | 50.116.355 | |
2022-07-05 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1.428.571 | 5.038.983 | 39,57 | 2,10 | 2.999.999 | 10.581.864 | |
2022-07-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 1.101.362 | 4.797.278 | 29,80 | 2,99 | 3.293.072 | 14.343.861 | |
2022-07-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 270.000 | 3.695.916 | 7,88 | 2,99 | 807.300 | 11.050.789 | |
2022-05-27 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 69.000 | 2.730.251 | 2,59 | 3,13 | 215.970 | 8.545.686 | |
2022-05-27 |
|
4 | ATHA |
Athira Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 13.871 | 13.871 | |||||
2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 120.000 | 2.661.251 | 4,72 | 2,63 | 315.600 | 6.999.090 | |
2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 42.551 | 2.541.251 | 1,70 | 2,47 | 105.101 | 6.276.890 | |
2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 8.700 | 2.498.700 | 0,35 | 2,49 | 21.663 | 6.221.763 | |
2022-04-18 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 157.515 | 5.321.032 | 3,05 | 22,22 | 3.499.983 | 118.233.331 | |
2022-04-14 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 5.924.170 | 7.858.285 | 306,30 | 4,22 | 24.999.997 | 33.161.963 | |
2021-12-10 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 200.000 | 9.111.151 | 2,24 | 5,36 | 1.072.000 | 48.835.769 | |
2021-12-03 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -2.707.463 | 52.334.993 | -4,92 | 3,31 | -8.961.703 | 173.228.827 | |
2021-11-05 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 20.000 | 27.858.895 | 0,07 | 13,51 | 270.200 | 376.373.671 | |
2021-11-05 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 2.250.000 | 27.838.895 | 8,79 | 16,00 | 36.000.000 | 445.422.320 | |
2021-11-03 |
|
4 | LIAN |
LianBio
Series A Preferred Shares |
C - Conversion | -423.579 | 0 | -100,00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -500.000 | 0 | -100,00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Series A Preferred Shares |
C - Conversion | -635.369 | 0 | -100,00 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 2.477.005 | 2.477.005 | |||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 2.923.000 | 4.330.675 | 207,65 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 14.619.500 | 21.653.385 | 207,84 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 14.619.500 | 21.653.385 | 207,84 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 3.715.510 | 10.969.395 | 51,22 | ||||
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 100.000 | 7.253.885 | 1,40 | 13,50 | 1.350.000 | 97.927.448 | |
2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 120.000 | 7.153.885 | 1,71 | 15,50 | 1.860.000 | 110.885.218 | |
2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
7.033.885 | ||||||||
2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
7.033.885 | ||||||||
2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
1.406.775 | ||||||||
2021-10-25 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1.200.000 | 5.163.517 | 30,28 | 19,80 | 23.760.000 | 102.237.637 | |
2021-10-15 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
P - Purchase | 2.687.280 | 2.687.280 | |||||
2021-10-15 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 5.734.560 | 21.654.485 | 36,02 | 0,85 | 4.874.376 | 18.406.312 | |
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -24.629 | 0 | -100,00 | ||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -40.373 | 0 | -100,00 | ||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -325.014 | 0 | -100,00 | ||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
P - Purchase | 850.000 | 3.554.587 | 31,43 | 15,00 | 12.750.000 | 53.318.805 | |
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 204.949 | 204.949 | |||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 335.962 | 335.962 | |||||
2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 2.704.587 | 2.704.587 | |||||
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -7.306 | 2.487.019 | -0,29 | 13,40 | -97.900 | 33.326.055 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -9.351 | 2.494.325 | -0,37 | 13,15 | -122.966 | 32.800.374 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -12.475 | 2.503.676 | -0,50 | 12,03 | -150.074 | 30.119.222 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -2.462 | 2.516.151 | -0,10 | 13,66 | -33.631 | 34.370.623 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -5.038 | 2.518.613 | -0,20 | 12,90 | -64.990 | 32.490.108 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -286 | 2.523.651 | -0,01 | 15,05 | -4.304 | 37.980.948 | |
2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -13.082 | 2.523.937 | -0,52 | 14,80 | -193.614 | 37.354.268 | |
2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -137.495 | 13.262.375 | -1,03 | 1,12 | -153.994 | 14.853.860 | |
2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -82.505 | 13.399.870 | -0,61 | 1,16 | -95.706 | 15.543.849 | |
2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -40.603 | 13.482.375 | -0,30 | 1,22 | -49.536 | 16.448.498 | |
2021-09-29 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -250.000 | 13.522.978 | -1,82 | 1,23 | -307.500 | 16.633.263 | |
2021-09-29 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -250.000 | 13.772.978 | -1,78 | 1,26 | -315.000 | 17.353.952 | |
2021-09-28 |
|
4 | LPTX |
LEAP THERAPEUTICS, INC.
Warrants (right to buy) |
P - Purchase | 3.508.771 | 3.508.771 | 2,85 | 9.996.489 | 9.996.489 | ||
2021-09-28 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -780.000 | 14.022.978 | -5,27 | 1,27 | -990.600 | 17.809.182 | |
2021-08-31 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 68.047 | 5.086.727 | 1,36 | 30,23 | 2.057.061 | 153.771.757 | |
2021-08-31 |
|
4 | LABP |
Landos Biopharma, Inc.
Stock Option (Right to Buy) |
A - Award | 25.291 | 25.291 | |||||
2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 61.387 | 5.018.680 | 1,24 | 28,57 | 1.753.827 | 143.383.688 | |
2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 69.761 | 4.957.293 | 1,43 | 27,73 | 1.934.473 | 137.465.735 | |
2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 44.437 | 4.887.532 | 0,92 | 25,78 | 1.145.586 | 126.000.575 | |
2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -350.352 | 14.802.978 | -2,31 | 1,24 | -434.436 | 18.355.693 | |
2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -552.380 | 15.153.330 | -3,52 | 1,29 | -712.570 | 19.547.796 | |
2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -879.092 | 15.705.710 | -5,30 | 1,35 | -1.186.774 | 21.202.708 | |
2021-08-18 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -250.000 | 4.935.057 | -4,82 | 1,74 | -435.000 | 8.586.999 | |
2021-08-17 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -250.000 | 5.185.057 | -4,60 | 1,84 | -460.000 | 9.540.505 | |
2021-08-16 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -338.897 | 5.435.057 | -5,87 | 2,23 | -755.740 | 12.120.177 | |
2021-07-09 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 200.000 | 4.843.095 | 4,31 | 25,00 | 5.000.000 | 121.077.375 | |
2021-06-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -145.548 | 0 | -100,00 | 3,80 | -553.082 | ||
2021-06-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -500.709 | 0 | -100,00 | 3,80 | -1.902.694 | ||
2021-06-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2021-06-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Restricted Share Units |
A - Award | 15.000 | 15.000 | |||||
2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
J - Other | 2.914.113 | 8.911.151 | 48,59 | ||||
2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 5.500.000 | 5.997.038 | 1.106,56 | 10,00 | 55.000.000 | 59.970.380 | |
2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 7.063 | 497.038 | 1,44 | 10,05 | 70.983 | 4.995.232 | |
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Warrant (right to buy) |
X - Other | -465.936 | 0 | -100,00 | ||||
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Warrant (right to buy) |
X - Other | -1.602.888 | 0 | -100,00 | ||||
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -320.388 | 145.548 | -68,76 | 4,00 | -1.281.552 | 582.192 | |
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -1.102.179 | 500.709 | -68,76 | 4,00 | -4.408.716 | 2.002.836 | |
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
X - Other | 465.936 | 465.936 | 2,75 | 1.281.324 | 1.281.324 | ||
2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
X - Other | 1.602.888 | 1.602.888 | 2,75 | 4.407.942 | 4.407.942 | ||
2021-06-03 |
|
4 | ARYA |
ARYA Sciences Acquisition Corp III
Class A Ordinary Shares |
P - Purchase | 330.050 | 489.975 | 206,38 | 10,05 | 3.317.002 | 4.924.249 | |
2021-06-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 13.871 | 13.871 | |||||
2021-05-24 |
|
4 | ARYA |
ARYA Sciences Acquisition Corp III
Class A Ordinary Shares |
P - Purchase | 159.925 | 159.925 | 10,05 | 1.607.246 | 1.607.246 | ||
2021-05-07 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -1.000.000 | 5.773.954 | -14,76 | 3,67 | -3.670.000 | 21.190.411 | |
2021-05-04 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1.200.000 | 9.903.879 | 13,79 | 12,50 | 15.000.000 | 123.798.488 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.195.792 | 0 | -100,00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -949.992 | 0 | -100,00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
P - Purchase | 550.000 | 2.537.019 | 27,68 | 17,00 | 9.350.000 | 43.129.323 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
C - Conversion | 1.107.316 | 1.987.019 | 125,87 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
C - Conversion | 879.703 | 879.703 | |||||
2021-04-09 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 304.136 | 3.963.517 | 8,31 | 16,44 | 4.999.996 | 65.160.219 | |
2021-04-06 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 450.000 | 450.000 | |||||
2021-03-23 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 2.608.695 | 13.412.552 | 24,15 | 5,75 | 14.999.996 | 77.122.174 | |
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Series D-2 Convertible Preferred Stock |
C - Conversion | -14.462.623 | 0 | -100,00 | ||||
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Series D-1 Convertible Preferred Stock |
C - Conversion | -10.177.703 | 0 | -100,00 | ||||
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
P - Purchase | 850.000 | 3.314.032 | 34,50 | 19,00 | 16.150.000 | 62.966.608 | |
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
C - Conversion | 1.446.262 | 2.464.032 | 142,10 | ||||
2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
C - Conversion | 1.017.770 | 1.017.770 | |||||
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 34.951 | 7.299.751 | 0,48 | 14,60 | 510.285 | 106.576.365 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 64.730 | 7.264.800 | 0,90 | 13,80 | 893.274 | 100.254.240 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 1.771 | 7.200.070 | 0,02 | 13,10 | 23.200 | 94.320.917 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 86.671 | 7.198.299 | 1,22 | 12,53 | 1.085.988 | 90.194.686 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 34.611 | 7.111.628 | 0,49 | 11,38 | 393.873 | 80.930.327 | |
2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 27.453 | 7.077.017 | 0,39 | 11,14 | 305.826 | 78.837.969 | |
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -1.770.600 | 0 | -100,00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -2.857.795 | 0 | -100,00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -2.857.795 | 0 | -100,00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series A Preferred Stock |
C - Conversion | -2.941.769 | 0 | -100,00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series A Preferred Stock |
C - Conversion | -2.941.769 | 0 | -100,00 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 1.250.000 | 7.049.564 | 21,55 | 16,00 | 20.000.000 | 112.793.024 | |
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 1.770.600 | 1.770.600 | |||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.857.795 | 5.799.564 | 97,15 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.857.795 | 5.799.564 | 97,15 | ||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.941.769 | 2.941.769 | |||||
2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.941.769 | 2.941.769 | |||||
2021-02-03 | 3 | LABP |
Landos Biopharma, Inc.
Common Stock |
3.090.924 | ||||||||
2021-02-03 | 3 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
543.373 | ||||||||
2021-02-03 | 3 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
1.933.551 | ||||||||
2021-02-03 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock |
A - Award | 1.617 | 30.920 | 5,52 | 3.009,53 | 4.866.410 | 93.054.668 | |
2021-02-03 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock |
A - Award | 4.851 | 4.851 | 3.009,53 | 14.599.230 | 14.599.230 | ||
2021-02-01 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
P - Purchase | 4.219.409 | 27.095.819 | 18,44 | 2,37 | 9.999.999 | 64.217.091 | |
2021-01-27 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 311.111 | 3.425.916 | 9,99 | 22,50 | 6.999.998 | 77.083.110 | |
2021-01-26 | 3 | SCYX |
SCYNEXIS INC
Common Stock |
2.400.000 | ||||||||
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -33.849 | 1.800.000 | -1,85 | 8,95 | -302.949 | 16.110.000 | |
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -285.151 | 1.833.849 | -13,46 | 8,16 | -2.326.832 | 14.964.208 | |
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -95.000 | 2.120.000 | -4,29 | 7,38 | -701.100 | 15.645.600 | |
2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -185.000 | 2.215.000 | -7,71 | 7,43 | -1.374.550 | 16.457.450 | |
2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -550.000 | 2.660.542 | -17,13 | 1,48 | -814.000 | 3.937.602 | |
2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -674.352 | 3.210.542 | -17,36 | 1,68 | -1.132.911 | 5.393.711 | |
2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -325.648 | 3.884.894 | -7,73 | 1,80 | -586.166 | 6.992.809 | |
2021-01-21 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1.368.421 | 8.703.879 | 18,65 | 9,50 | 13.000.000 | 82.686.850 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 50.000 | 7.335.458 | 0,69 | 7,60 | 380.000 | 55.749.481 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 152.668 | 7.285.458 | 2,14 | 10,21 | 1.558.740 | 74.384.526 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 347.332 | 7.132.790 | 5,12 | 9,21 | 3.198.928 | 65.692.996 | |
2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 500.000 | 6.785.458 | 7,95 | 8,13 | 4.065.000 | 55.165.774 | |
2020-12-15 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 4.054.054 | 10.803.857 | 60,06 | 3,70 | 15.000.000 | 39.974.271 | |
2020-11-24 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 500.000 | 6.933.277 | 7,77 | 12,85 | 6.425.000 | 89.092.609 | |
2020-10-29 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common stock |
P - Purchase | 3.000.000 | 3.157.295 | 1.907,24 | 10,00 | 30.000.000 | 31.572.950 | |
2020-10-22 |
|
4 | ARYB |
ARYA Sciences Acquisition Corp II
Class A ordinary shares |
P - Purchase | 43.195 | 157.295 | 37,86 | 10,09 | 435.838 | 1.587.107 | |
2020-10-22 |
|
4 | ARYB |
ARYA Sciences Acquisition Corp II
Class A ordinary shares |
P - Purchase | 114.100 | 114.100 | 10,00 | 1.141.000 | 1.141.000 | ||
2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Series B Preferred Stock |
C - Conversion | -1.644.785 | 0 | -100,00 | ||||
2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 1.058.824 | 3.114.805 | 51,50 | 17,00 | 18.000.008 | 52.951.685 | |
2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
C - Conversion | 1.644.785 | 2.055.981 | 400,00 | ||||
2020-09-17 | 3 | ATHA |
Athira Pharma, Inc.
Common Stock |
411.196 | ||||||||
2020-09-16 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2.911.764 | 16.200.818 | 21,91 | 4,25 | 12.374.997 | 68.853.476 | |
2020-09-15 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 400.000 | 2.360.139 | 20,41 | 40,00 | 16.000.000 | 94.405.560 | |
2020-09-14 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 1.800.000 | 13.532.467 | 15,34 | 11,00 | 19.800.000 | 148.857.137 | |
2020-09-14 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 200.000 | 11.732.467 | 1,73 | 11,24 | 2.248.000 | 131.872.929 | |
2020-07-13 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 3.200.000 | 6.285.458 | 103,71 | 4,25 | 13.600.000 | 26.713.196 | |
2020-06-24 |
|
4 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
P - Purchase | 1.750.000 | 8.476.496 | 26,02 | 2,00 | 3.500.000 | 16.952.992 | |
2020-06-18 |
|
4 | SLDB |
Solid Biosciences Inc.
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
2020-06-11 |
|
4 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
P - Purchase | 2.702.702 | 22.876.410 | 13,40 | 1,85 | 4.999.999 | 42.321.358 | |
2020-06-04 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 25.000 | 25.000 | |||||
2020-05-29 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 625.000 | 1.934.115 | 47,74 | 16,00 | 10.000.000 | 30.945.840 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -339.604 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -141.221 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -16.232.511 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -39.035.325 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -26.666.666 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
F - Taxes | -183.174 | 1.288.446 | -12,45 | 16,00 | -2.930.784 | 20.615.136 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 339.604 | 1.471.620 | 30,00 | 8,63 | 2.930.783 | 12.700.081 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
F - Taxes | -76.172 | 1.309.115 | -5,50 | 16,00 | -1.218.752 | 20.945.840 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 141.221 | 1.385.287 | 11,35 | 8,63 | 1.218.737 | 11.955.027 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 470.739 | 1.244.066 | 60,87 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1.132.016 | 1.132.016 | |||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 773.327 | 773.327 | |||||
2020-05-01 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Stock Option |
A - Award | 14.500 | 14.500 | |||||
2020-05-01 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Stock Option |
A - Award | 14.500 | 14.500 | |||||
2020-04-28 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 9.090.909 | 55.042.456 | 19,78 | 1,10 | 10.000.000 | 60.546.702 | |
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
2020-04-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1.071.428 | 3.659.381 | 41,40 | 14,00 | 14.999.992 | 51.231.334 | |
2020-03-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 500.000 | 16.584.802 | 3,11 | 2,10 | 1.050.000 | 34.828.084 | |
2020-03-17 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 1.000.000 | 15.919.925 | 6,70 | 1,75 | 1.750.000 | 27.859.869 | |
2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 3.000.000 | 14.919.925 | 25,17 | 3,00 | 9.000.000 | 44.759.775 | |
2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 700.000 | 700.000 | |||||
2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 700.000 | 700.000 | |||||
2020-02-11 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 4.563.700 | 16.084.802 | 39,61 | 3,50 | 15.972.950 | 56.296.807 | |
2020-02-04 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 255.809 | 1.960.139 | 15,01 | 21,00 | 5.371.989 | 41.162.919 | |
2019-12-27 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 73.698 | 11.532.467 | 0,64 | 14,39 | 1.060.514 | 165.952.200 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 153.237 | 11.458.769 | 1,36 | 14,30 | 2.191.289 | 163.860.397 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 189.322 | 11.305.532 | 1,70 | 14,14 | 2.677.013 | 159.860.222 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 120.931 | 11.116.210 | 1,10 | 13,86 | 1.676.104 | 154.070.671 | |
2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 142.812 | 10.995.279 | 1,32 | 13,72 | 1.959.381 | 150.855.228 | |
2019-11-18 |
|
4 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
P - Purchase | 1.470.588 | 14.636.334 | 11,17 | 3,40 | 4.999.999 | 49.763.536 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 333.800 | 11.919.925 | 2,88 | 1,74 | 580.812 | 20.740.670 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 2.000.000 | 11.586.125 | 20,86 | 1,60 | 3.200.000 | 18.537.800 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 3.000.000 | 9.586.125 | 45,55 | 1,72 | 5.160.000 | 16.488.135 | |
2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 435.015 | 6.586.125 | 7,07 | 1,69 | 735.175 | 11.130.551 | |
2019-11-15 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
J - Other | -3.125.851 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2.500.000 | 13.289.054 | 23,17 | 7,00 | 17.500.000 | 93.023.378 | |
2019-10-31 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -760.291 | 6.151.110 | -11,00 | 0,44 | -334.528 | 2.706.488 | |
2019-10-30 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -3.815.349 | 6.911.401 | -35,57 | 0,51 | -1.945.828 | 3.524.815 | |
2019-10-30 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 2.300.000 | 10.726.750 | 27,29 | 0,95 | 2.185.000 | 10.190.412 | |
2019-10-21 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 50.000 | 10.852.467 | 0,46 | 10,93 | 546.500 | 118.617.464 | |
2019-10-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 67.222 | 10.802.467 | 0,63 | 10,29 | 691.714 | 111.157.385 | |
2019-09-24 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 20.000.000 | 45.951.556 | 77,07 | 0,50 | 10.000.000 | 22.975.778 | |
2019-09-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30.000 | 10.735.245 | 0,28 | 13,58 | 407.400 | 145.784.627 | |
2019-09-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 56.416 | 10.705.245 | 0,53 | 14,27 | 805.056 | 152.763.846 | |
2019-09-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 13.584 | 10.648.829 | 0,13 | 14,05 | 190.855 | 149.616.047 | |
2019-08-20 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 425.531 | 6.433.277 | 7,08 | 23,50 | 9.999.978 | 151.182.010 | |
2019-08-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 20.000 | 10.635.245 | 0,19 | 14,96 | 299.200 | 159.103.265 | |
2019-08-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30.000 | 10.615.245 | 0,28 | 15,00 | 450.000 | 159.228.675 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30.000 | 10.585.245 | 0,28 | 15,76 | 472.800 | 166.823.461 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 37.764 | 10.555.245 | 0,36 | 15,79 | 596.294 | 166.667.319 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 248.752 | 10.517.481 | 2,42 | 15,04 | 3.741.230 | 158.182.914 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 371.756 | 10.268.729 | 3,76 | 14,14 | 5.256.630 | 145.199.828 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 74.855 | 9.896.973 | 0,76 | 13,12 | 982.098 | 129.848.286 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 1.495 | 9.822.118 | 0,02 | 17,89 | 26.746 | 175.717.691 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 20.786 | 9.820.623 | 0,21 | 17,90 | 372.069 | 175.789.152 | |
2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 23.073 | 9.799.837 | 0,24 | 17,85 | 411.853 | 174.927.090 | |
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
2019-07-29 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 2.822.581 | 6.749.803 | 71,87 | 4,65 | 13.125.002 | 31.386.584 | |
2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 42.916 | 3.708.705 | 1,17 | 16,67 | 715.410 | 61.824.112 | |
2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 12.354 | 3.665.789 | 0,34 | 16,89 | 208.659 | 61.915.176 | |
2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29.834 | 3.653.435 | 0,82 | 16,61 | 495.543 | 60.683.555 | |
2019-07-09 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 50.000 | 3.632.601 | 1,40 | 16,46 | 823.000 | 59.792.612 | |
2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1.705 | 3.573.601 | 0,05 | 16,67 | 28.422 | 59.571.929 | |
2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 715 | 3.571.896 | 0,02 | 16,14 | 11.540 | 57.650.401 | |
2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 18.121 | 3.571.181 | 0,51 | 14,24 | 258.043 | 50.853.617 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 39.383 | 3.553.060 | 1,12 | 14,48 | 570.266 | 51.448.309 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 60.617 | 3.513.560 | 1,76 | 13,97 | 846.819 | 49.084.433 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 186.696 | 3.453.060 | 5,72 | 13,58 | 2.535.332 | 46.892.555 | |
2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 140.513 | 3.266.364 | 4,50 | 12,46 | 1.750.792 | 40.698.895 | |
2019-07-01 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 1.000.000 | 4.210.542 | 31,15 | 3,00 | 3.000.000 | 12.631.626 | |
2019-06-21 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 25.000 | 25.000 | |||||
2019-06-20 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 1.000.000 | 25.951.556 | 4,01 | 0,65 | 650.000 | 16.868.511 | |
2019-06-20 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 50.742 | 9.776.764 | 0,52 | 17,73 | 899.656 | 173.342.026 | |
2019-06-19 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 130.000 | 9.726.022 | 1,35 | 17,94 | 2.332.200 | 174.484.835 | |
2019-06-18 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 1.000.000 | 24.951.556 | 4,18 | 0,62 | 618.000 | 15.420.062 | |
2019-06-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 324.290 | 9.596.022 | 3,50 | 17,69 | 5.736.690 | 169.753.629 | |
2019-06-17 |
|
4 | SLDB |
Solid Biosciences Inc.
Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
2019-06-17 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 75.710 | 9.271.732 | 0,82 | 17,05 | 1.290.856 | 158.083.031 | |
2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 4.000.000 | 11.521.102 | 53,18 | 4,00 | 16.000.000 | 46.084.408 | |
2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Warrants (right to buy) |
P - Purchase | 250.000 | 250.000 | |||||
2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Warrants (right to buy) |
P - Purchase | 1.360.000 | 1.360.000 | |||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
2019-05-08 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 77.010 | 9.196.022 | 0,84 | 12,90 | 993.429 | 118.628.684 | |
2019-05-08 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 22.990 | 9.119.012 | 0,25 | 12,08 | 277.719 | 110.157.665 | |
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
2019-03-05 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1.304.348 | 6.007.746 | 27,73 | 13,80 | 18.000.002 | 82.906.895 | |
2019-01-17 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 400.000 | 3.210.541 | 14,23 | 2,70 | 1.080.000 | 8.668.461 | |
2019-01-17 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 10.000 | 2.810.541 | 0,36 | 5,00 | 50.000 | 14.052.705 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -450.235 | 2.253.376 | -16,65 | 5,26 | -2.368.236 | 11.852.758 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -800.000 | 2.703.611 | -22,83 | 5,25 | -4.200.000 | 14.193.958 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -25.800 | 3.503.611 | -0,73 | 6,46 | -166.668 | 22.633.327 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -25.800 | 3.503.611 | -0,73 | 6,46 | -166.668 | 22.633.327 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4.200 | 3.529.411 | -0,12 | 5,26 | -22.092 | 18.564.702 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4.200 | 3.529.411 | -0,12 | 5,26 | -22.092 | 18.564.702 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4.592 | 3.563.611 | -0,13 | 9,52 | -43.716 | 33.925.577 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -34.401 | 3.568.203 | -0,95 | 9,05 | -311.329 | 32.292.237 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -131.866 | 3.602.604 | -3,53 | 7,56 | -996.907 | 27.235.686 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -147.497 | 3.734.470 | -3,80 | 6,67 | -983.805 | 24.908.915 | |
2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -431.644 | 3.881.967 | -10,01 | 5,64 | -2.434.472 | 21.894.294 | |
2018-12-17 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 14.285.714 | 23.631.439 | 152,86 | 1,40 | 20.000.000 | 33.084.015 | |
2018-12-10 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2.000.000 | 10.789.054 | 22,76 | 6,50 | 13.000.000 | 70.128.851 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -2.350.000 | 2.724.686 | -46,31 | 12,52 | -29.422.000 | 34.113.069 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -500.000 | 5.074.686 | -8,97 | 12,51 | -6.255.000 | 63.484.322 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -500.000 | 5.574.686 | -8,23 | 12,50 | -6.250.000 | 69.683.575 | |
2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -282.447 | 6.074.686 | -4,44 | 12,51 | -3.533.412 | 75.994.322 | |
2018-10-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 30.000 | 20.724.424 | 0,14 | 12,69 | 380.700 | 262.992.941 | |
2018-10-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 20.000 | 20.694.424 | 0,10 | 12,45 | 249.000 | 257.645.579 | |
2018-09-25 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 50.000 | 20.674.424 | 0,24 | 12,53 | 626.500 | 259.050.533 | |
2018-09-17 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100.000 | 20.624.424 | 0,49 | 11,74 | 1.174.000 | 242.130.738 | |
2018-09-14 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 500.000 | 20.524.424 | 2,50 | 12,00 | 6.001.500 | 246.354.661 | |
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6.186.205 | 0 | -100,00 | ||||
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 400.000 | 2.587.953 | 18,28 | 17,00 | 6.800.000 | 43.995.201 | |
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.880.305 | 2.187.953 | 611,19 | ||||
2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 307.648 | 307.648 | 21,30 | 6.552.902 | 6.552.902 | ||
2018-08-14 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 100.000 | 4.070.357 | 2,52 | 52,00 | 5.200.000 | 211.658.564 | |
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Series C Preferred Stock |
C - Conversion | -2.193.463 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Series B Preferred Stock |
C - Conversion | -1.937.984 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1.000.000 | 3.410.412 | 41,49 | 15,00 | 15.000.000 | 51.156.180 | |
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
C - Conversion | 1.279.733 | 2.410.412 | 113,18 | ||||
2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
C - Conversion | 1.130.679 | 1.130.679 | |||||
2018-07-27 |
|
4 | SLDB |
Solid Biosciences Inc.
Stock Option (Right to Buy) |
A - Award | 1.835 | 1.835 | |||||
2018-07-26 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -298.628 | 3.231.372 | -8,46 | 0,30 | -89.439 | 967.796 | |
2018-07-20 |
|
4 | QTNT |
Quotient Ltd
Warrants (right to buy) |
X - Other | -2.306.034 | 0 | -100,00 | ||||
2018-07-20 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
X - Other | 2.306.034 | 8.789.054 | 35,57 | 5,80 | 13.374.997 | 50.976.513 | |
2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6.186.205 | 0 | -100,00 | ||||
2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 400.000 | 2.280.305 | 21,27 | 17,00 | 6.800.000 | 38.765.185 | |
2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.880.305 | 1.880.305 | |||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
2018-06-13 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 5.591 | 3.125.851 | 0,18 | 29,82 | 166.724 | 93.212.877 | |
2018-06-13 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 14.109 | 3.120.260 | 0,45 | 29,18 | 411.701 | 91.049.187 | |
2018-06-12 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2.000 | 3.106.151 | 0,06 | 28,97 | 57.940 | 89.985.194 | |
2018-06-12 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 23.000 | 3.104.151 | 0,75 | 28,62 | 658.260 | 88.840.802 | |
2018-06-12 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1.333.333 | 4.703.398 | 39,56 | 15,00 | 19.999.995 | 70.550.970 | |
2018-06-12 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 50.000 | 3.370.065 | 1,51 | 15,22 | 761.000 | 51.292.389 | |
2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 8.400 | 3.081.151 | 0,27 | 29,16 | 244.944 | 89.846.363 | |
2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 19.223 | 3.072.751 | 0,63 | 28,40 | 545.933 | 87.266.128 | |
2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 22.377 | 3.053.528 | 0,74 | 27,63 | 618.277 | 84.368.979 | |
2018-06-08 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 51.763 | 3.031.151 | 1,74 | 28,99 | 1.500.609 | 87.873.067 | |
2018-06-08 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 48.237 | 2.979.388 | 1,65 | 28,30 | 1.365.107 | 84.316.680 | |
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 3.168 | 2.931.151 | 0,11 | 27,13 | 85.948 | 79.522.127 | |
2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 56.162 | 2.927.983 | 1,96 | 26,31 | 1.477.622 | 77.035.233 | |
2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 40.670 | 2.871.821 | 1,44 | 25,45 | 1.035.052 | 73.087.844 | |
2018-06-06 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 10.000 | 2.831.151 | 0,35 | 25,07 | 250.700 | 70.976.956 | |
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
2018-05-24 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 231.992 | 6.483.020 | 3,71 | 6,65 | 1.542.747 | 43.112.083 | |
2018-05-24 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 218.008 | 6.251.028 | 3,61 | 6,24 | 1.360.370 | 39.006.415 | |
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
2018-03-26 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 700.000 | 4.313.611 | 19,37 | 29,50 | 20.650.000 | 127.251.524 | |
2018-03-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 335.827 | 18.424.424 | 1,86 | 13,56 | 4.553.814 | 249.835.189 | |
2018-03-06 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100.000 | 18.088.597 | 0,56 | 13,90 | 1.389.500 | 251.341.055 | |
2018-03-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100.000 | 17.988.597 | 0,56 | 13,69 | 1.369.000 | 246.263.893 | |
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -256.386 | 0 | -100,00 | ||||
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 1.000.000 | 2.800.541 | 55,54 | 5,00 | 5.000.000 | 14.002.705 | |
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
C - Conversion | 256.386 | 1.800.541 | 16,60 | ||||
2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Warrant (right to buy) |
J - Other | 180.055 | 180.055 | |||||
2018-02-20 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 50.000 | 3.613.611 | 1,40 | 32,42 | 1.621.000 | 117.153.269 | |
2018-02-15 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 100.000 | 3.563.611 | 2,89 | 32,69 | 3.269.000 | 116.494.444 | |
2018-02-15 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 75.000 | 3.463.611 | 2,21 | 32,75 | 2.456.250 | 113.433.260 | |
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
2018-01-30 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 20.000 | 3.927.222 | 0,51 | 27,33 | 546.520 | 107.315.268 | |
2018-01-30 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 1.000.000 | 3.907.222 | 34,40 | 16,00 | 16.000.000 | 62.515.552 | |
2018-01-25 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 275.000 | 1.595.000 | 20,83 | 33,00 | 9.075.000 | 52.635.000 | |
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 310.000 | 6.357.133 | 5,13 | 12,80 | 3.968.000 | 81.371.302 | |
2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 149.650 | 6.047.133 | 2,54 | 12,24 | 1.831.716 | 74.016.908 | |
2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 50.350 | 5.897.483 | 0,86 | 11,83 | 595.640 | 69.767.224 | |
2017-12-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 175.000 | 4.889.066 | 3,71 | 38,00 | 6.650.000 | 185.784.508 | |
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
2017-11-01 | 3/A | QTNT |
Quotient Ltd
Ordinary Shares |
6.033.020 | ||||||||
2017-10-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 3.100.000 | 9.345.725 | 49,63 | 3,05 | 9.455.000 | 28.504.461 | |
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 22.055 | 3.670.357 | 0,60 | 27,67 | 610.341 | 101.571.991 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8.920 | 3.648.302 | 0,25 | 40,14 | 358.081 | 146.455.976 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 12.586 | 3.639.382 | 0,35 | 39,22 | 493.600 | 142.730.011 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8.112 | 3.626.796 | 0,22 | 38,56 | 312.791 | 139.845.990 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 6.153 | 3.618.684 | 0,17 | 37,14 | 228.530 | 134.402.266 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 3.800 | 3.612.531 | 0,11 | 36,26 | 137.805 | 131.006.630 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 6.000 | 3.608.731 | 0,17 | 34,91 | 209.475 | 125.989.821 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8.260 | 3.602.731 | 0,23 | 33,86 | 279.665 | 121.980.185 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 15.937 | 3.594.471 | 0,45 | 32,96 | 525.311 | 118.479.875 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 102.199 | 3.578.534 | 2,94 | 31,90 | 3.260.240 | 114.158.455 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 28.033 | 3.476.335 | 0,81 | 31,19 | 874.220 | 108.410.898 | |
2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 300.000 | 3.970.357 | 8,17 | 37,50 | 11.250.000 | 148.888.388 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -350.000 | 2.099.563 | -14,29 | 3,35 | -1.172.500 | 7.033.536 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -500.000 | 2.449.563 | -16,95 | 3,27 | -1.633.250 | 8.001.498 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -250.000 | 2.949.563 | -7,81 | 3,17 | -792.500 | 9.350.115 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -250.000 | 3.199.563 | -7,25 | 3,03 | -757.250 | 9.691.476 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -300.000 | 3.449.563 | -8,00 | 3,09 | -926.250 | 10.650.526 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -353.421 | 3.749.563 | -8,61 | 3,56 | -1.258.143 | 13.348.069 | |
2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -126.579 | 4.102.984 | -2,99 | 3,74 | -473.659 | 15.353.366 | |
2017-09-21 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 200.000 | 3.085.458 | 6,93 | 7,25 | 1.450.000 | 22.369.570 | |
2017-07-14 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 1.500.000 | 17.888.597 | 9,15 | 12,25 | 18.375.000 | 219.135.313 | |
2017-07-05 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 301.004 | 5.847.133 | 5,43 | 7,70 | 2.319.236 | 45.052.160 | |
2017-07-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 296.007 | 2.885.458 | 11,43 | 4,60 | 1.361.632 | 13.273.107 | |
2017-07-05 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 175.653 | 3.448.302 | 5,37 | 14,45 | 2.538.186 | 49.827.964 | |
2017-06-21 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -875.000 | 4.533.728 | -16,18 | 2,40 | -2.100.000 | 10.880.947 | |
2017-05-25 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 1.902.400 | 5.546.129 | 52,21 | 6,25 | 11.890.000 | 34.663.306 | |
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
2017-03-20 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
9.910.948 | ||||||||
2017-03-20 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
9.910.948 | ||||||||
2017-03-14 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 59.133 | 4.229.563 | 1,42 | 15,51 | 917.425 | 65.619.978 | |
2017-03-14 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 34.883 | 4.170.430 | 0,84 | 14,94 | 521.281 | 62.321.655 | |
2017-02-15 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 893.025 | 2.589.451 | 52,64 | 4,50 | 4.018.612 | 11.652.530 | |
2017-02-14 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 59.133 | 4.228.563 | 1,42 | 15,51 | 917.425 | 65.604.464 | |
2017-02-14 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 34.883 | 4.169.430 | 0,84 | 14,94 | 521.281 | 62.306.711 | |
2017-02-10 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 41.211 | 4.134.547 | 1,01 | 14,27 | 587.928 | 58.984.688 | |
2017-02-10 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 104.612 | 4.093.336 | 2,62 | 13,51 | 1.413.319 | 55.301.379 | |
2017-01-04 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 94.750 | 4.013.411 | 2,42 | 14,66 | 1.388.846 | 58.828.578 | |
2017-01-04 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 94.750 | 16.293.847 | 0,58 | 4,96 | 470.055 | 80.833.775 | |
2017-01-04 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 71.063 | 3.989.724 | 1,81 | 14,66 | 1.041.641 | 58.481.374 | |
2016-12-30 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 47.375 | 3.918.661 | 1,22 | 14,37 | 680.589 | 56.295.484 | |
2016-12-30 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 94.750 | 16.293.847 | 0,58 | 4,85 | 459.916 | 79.090.333 | |
2016-12-30 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 47.375 | 16.199.097 | 0,29 | 4,91 | 232.706 | 79.569.964 | |
2016-12-27 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 37.900 | 16.151.722 | 0,24 | 4,92 | 186.582 | 79.514.927 | |
2016-12-27 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 47.375 | 16.113.822 | 0,29 | 4,72 | 223.468 | 76.008.898 | |
2016-12-23 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 189.500 | 16.066.447 | 1,19 | 4,51 | 854.834 | 72.475.742 | |
2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Warrant |
P - Purchase | 1.341.282 | 2.068.824 | 184,36 | 3,36 | 4.500.001 | 6.940.905 | |
2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Warrant |
P - Purchase | 363.771 | 727.542 | 100,00 | 4,13 | 1.502.374 | 3.004.748 | |
2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Common Stock |
P - Purchase | 3.383.955 | 6.213.314 | 119,60 | 3,05 | 10.321.063 | 18.950.608 | |
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
2016-12-02 | 3/A | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
15.876.947 | ||||||||
2016-10-05 | 3/A | VSAR |
Versartis, Inc.
Common Stock |
3.871.286 | ||||||||
2016-09-30 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -97.200 | 5.386.410 | -1,77 | 3,88 | -377.117 | 20.898.194 | |
2016-09-30 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -119.300 | 5.483.610 | -2,13 | 3,96 | -472.380 | 21.712.902 | |
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
2016-09-16 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -115.923 | 5.602.910 | -2,03 | 3,63 | -420.511 | 20.324.556 | |
2016-09-16 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -276.927 | 5.718.833 | -4,62 | 3,73 | -1.032.301 | 21.318.094 | |
2016-08-26 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
S - Sale | -1.100.000 | 14.139.444 | -7,22 | 6,81 | -7.491.000 | 96.289.614 | |
2016-05-26 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 700.000 | 1.940.458 | 56,43 | 5,00 | 3.500.000 | 9.702.290 | |
2015-11-19 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -42.300 | 5.995.760 | -0,70 | 5,35 | -226.132 | 32.052.733 | |
2015-11-19 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -133.900 | 6.038.060 | -2,17 | 5,36 | -717.409 | 32.350.718 | |
2015-11-09 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -17.100 | 6.171.960 | -0,28 | 4,47 | -76.365 | 27.562.739 | |
2015-11-09 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -75.000 | 6.189.060 | -1,20 | 4,62 | -346.260 | 28.573.652 | |
2015-11-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 45.100 | 1.240.458 | 3,77 | 6,50 | 293.150 | 8.062.977 | |
2015-10-28 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 50.000 | 1.195.358 | 4,37 | 6,46 | 323.150 | 7.725.599 | |
2015-10-26 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 18.020 | 1.145.358 | 1,60 | 6,47 | 116.661 | 7.415.048 | |
2015-10-22 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 22.797 | 1.127.338 | 2,06 | 6,44 | 146.858 | 7.262.311 | |
2015-10-22 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 14.348 | 1.104.541 | 1,32 | 6,30 | 90.335 | 6.954.190 | |
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
2015-10-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 50.000 | 15.239.444 | 0,33 | 6,27 | 313.500 | 95.551.314 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 7.000 | 15.189.444 | 0,05 | 6,34 | 44.380 | 96.301.075 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 14.000 | 15.182.444 | 0,09 | 6,47 | 90.580 | 98.230.413 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 14.000 | 15.168.444 | 0,09 | 6,65 | 93.100 | 100.870.153 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 43.000 | 15.154.444 | 0,28 | 6,34 | 272.620 | 96.079.175 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 86.000 | 15.111 | -121,32 | 6,47 | 556.420 | 97.771 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 86.000 | 15.025.444 | 0,58 | 6,65 | 571.900 | 99.919.203 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 35.000 | 14.939.444 | 0,23 | 6,76 | 236.600 | 100.990.641 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 35.000 | 14.904.444 | 0,24 | 6,85 | 239.750 | 102.095.441 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 215.000 | 14.869.444 | 1,47 | 6,76 | 1.453.400 | 100.517.441 | |
2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 215.000 | 14.654.444 | 1,49 | 6,85 | 1.472.750 | 100.382.941 | |
2015-09-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -310.000 | 6.264.060 | -4,72 | 4,18 | -1.294.777 | 26.163.099 | |
2015-08-18 |
|
4 | VBIV |
VBI VACCINES INC.
Common Stock |
P - Purchase | 650.000 | 3.260.356 | 24,90 | 2,08 | 1.352.000 | 6.781.540 | |
2014-11-19 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 2.100.000 | 14.439.444 | 17,02 | 6,50 | 13.650.000 | 93.856.386 | |
2014-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 530.000 | 12.339.444 | 4,49 | 3,50 | 1.855.000 | 43.188.054 | |
2014-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 3.470.000 | 11.809.444 | 41,61 | 3,50 | 12.145.000 | 41.333.054 | |
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.500 | 6.574.060 | 0,10 | 6,50 | 42.238 | 42.718.899 | |
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 93.500 | 6.567.560 | 1,44 | 6,50 | 607.572 | 42.676.662 | |
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.500 | 6.474.060 | 0,10 | 6,52 | 42.358 | 42.188.859 | |
2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 93.500 | 6.467.560 | 1,47 | 6,52 | 609.302 | 42.146.501 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.250 | 6.374.060 | 0,05 | 6,84 | 22.220 | 43.579.448 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 46.750 | 6.370.810 | 0,74 | 6,84 | 319.630 | 43.557.228 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.825 | 6.324.060 | 0,11 | 6,88 | 46.959 | 43.512.062 | |
2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 98.175 | 6.317.235 | 1,58 | 6,88 | 675.483 | 43.465.104 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 150.218 | 6.219.060 | 2,48 | 7,17 | 1.077.033 | 44.589.416 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 10.442 | 6.068.842 | 0,17 | 7,17 | 74.867 | 43.512.383 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.000 | 6.058.400 | 0,13 | 6,69 | 53.546 | 40.550.083 | |
2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 192.000 | 6.050.400 | 3,28 | 6,69 | 1.285.094 | 40.496.537 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
S - Sale | -50.000 | 2.823.426 | -1,74 | 89,20 | -4.460.000 | 251.849.599 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
S - Sale | -700.000 | 2.873.426 | -19,59 | 89,20 | -62.440.000 | 256.309.599 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
X - Other | -1.000 | 0 | -100,00 | ||||
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
X - Other | -1.000 | 0 | -100,00 | ||||
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
X - Other | 100.000 | 3.573.426 | 2,88 | 25,00 | 2.500.000 | 89.335.650 | |
2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
X - Other | 100.000 | 3.473.426 | 2,96 | 25,00 | 2.500.000 | 86.835.650 | |
2013-07-24 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 850.000 | 5.858.400 | 16,97 | 11,65 | 9.902.500 | 68.250.360 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22.000 | 2,33 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22.000 | 2,33 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22.500 | 2,27 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 23.000 | 2,22 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 23.500 | 2,17 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 24.000 | 4,35 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 24.000 | 4,35 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 25.000 | 4,17 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.500 | 26.000 | 6,12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 2.000 | 27.500 | 7,84 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 2.000 | 27.500 | 7,84 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 6.000 | 29.500 | 25,53 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 36.000 | 2,86 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 4.000 | 40.000 | 11,11 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44.000 | 1,15 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44.000 | 1,15 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44.500 | 1,14 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 45.000 | 1,12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 45.500 | 2,25 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 45.500 | 2,25 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | ||||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 47.500 | 2,15 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 48.500 | 2,11 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.500 | 49.500 | 3,12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.500 | 49.500 | 3,12 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 4.000 | 51.000 | 8,51 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 4.000 | 51.000 | 8,51 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 55.000 | 1,85 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 2.000 | 56.000 | 3,70 | ||||
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 812.560 | -5,80 | 10,00 | -500.000 | 8.125.600 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 812.560 | -5,80 | 10,00 | -500.000 | 8.125.600 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 862.560 | -5,48 | 12,50 | -625.000 | 10.782.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 862.560 | -5,48 | 12,50 | -625.000 | 10.782.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 862.560 | -5,48 | 12,50 | -625.000 | 10.782.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 962.560 | -9,41 | 12,50 | -1.250.000 | 12.032.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 962.560 | -9,41 | 12,50 | -1.250.000 | 12.032.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 962.560 | -9,41 | 12,50 | -1.250.000 | 12.032.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 1.162.560 | -7,92 | 10,00 | -1.000.000 | 11.625.600 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -150.000 | 1.362.560 | -9,92 | 12,50 | -1.875.000 | 17.032.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -400.000 | 1.512.560 | -20,91 | 12,50 | -5.000.000 | 18.907.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -400.000 | 1.512.560 | -20,91 | 12,50 | -5.000.000 | 18.907.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -200.000 | 2.012.560 | -9,04 | 12,50 | -2.500.000 | 25.157.000 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -150.000 | 2.612.560 | -5,43 | 15,00 | -2.250.000 | 39.188.400 | |
2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 2.762.560 | -3,49 | 10,00 | -1.000.000 | 27.625.600 | |
2013-03-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 64.500 | 0,78 | 2,76 | 1.380 | 178.020 | |
2013-03-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 64.000 | 1,59 | 1,94 | 1.945 | 124.480 | |
2013-03-06 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
P - Purchase | 1.000 | 2.000 | 100,00 | 8,26 | 8.260 | 16.520 | |
2013-03-06 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
P - Purchase | 1.000 | 2.000 | 100,00 | 8,26 | 8.260 | 16.520 | |
2013-02-27 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 63.000 | 0,80 | 0,90 | 450 | 56.700 | |
2013-02-27 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 62.500 | -0,79 | 1,05 | -525 | 65.625 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 62.000 | 0,81 | 0,78 | 390 | 48.360 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 61.500 | -0,81 | 1,04 | -520 | 63.960 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 61.000 | 1,67 | 0,79 | 790 | 48.190 | |
2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 60.000 | -1,64 | 0,89 | -890 | 53.400 | |
2013-02-13 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 59.000 | 1,72 | 2,08 | 2.080 | 122.720 | |
2013-02-13 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 58.000 | -1,69 | 0,38 | -380 | 22.040 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.500 | 57.000 | 2,70 | 2,33 | 3.495 | 132.810 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.500 | 55.500 | -2,63 | 0,27 | -405 | 14.985 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 4.000 | 54.000 | 8,00 | 1,65 | 6.600 | 89.100 | |
2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 50.000 | -3,85 | 0,55 | -1.100 | 27.500 | |
2013-02-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -6.000 | 48.000 | -11,11 | 0,69 | -4.140 | 33.120 | |
2013-02-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 42.000 | -1,18 | 2,05 | -1.025 | 86.100 | |
2013-02-05 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50.000 | 3.373.426 | 1,50 | 27,79 | 1.389.400 | 93.740.762 | |
2013-02-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 41.500 | -2,35 | 0,80 | -800 | 33.200 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 40.500 | 2,53 | 1,45 | 1.450 | 58.725 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 39.500 | -2,47 | 0,88 | -875 | 34.562 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 38.500 | 5,48 | 1,32 | 2.650 | 51.012 | |
2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 36.500 | -5,19 | 1,05 | -2.100 | 38.325 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 4.000 | 34.500 | 13,11 | 1,71 | 6.840 | 58.995 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to buy) |
P - Purchase | 500 | 30.500 | 1,67 | 0,05 | 25 | 1.525 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to buy) |
P - Purchase | 500 | 30.000 | 1,69 | 0,10 | 50 | 3.000 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -4.000 | 29.500 | -11,94 | 0,80 | -3.200 | 23.600 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 25.500 | 8,51 | 1,50 | 3.000 | 38.250 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 23.500 | 9,30 | 1,85 | 3.700 | 43.475 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 21.500 | 10,26 | 0,65 | 1.300 | 13.979 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.500 | 19.500 | 8,33 | 2,87 | 4.300 | 55.901 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 18.000 | 5,88 | 0,80 | 800 | 14.400 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 17.000 | -5,56 | 1,19 | -1.190 | 20.230 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 16.000 | -5,88 | 2,43 | -2.428 | 38.846 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 15.000 | -6,25 | 0,80 | -800 | 12.000 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 14.000 | -12,50 | 1,47 | -2.935 | 20.545 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 12.000 | -14,29 | 1,00 | -2.001 | 12.004 | |
2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 10.000 | -16,67 | 0,88 | -1.757 | 8.787 | |
2013-01-23 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 8.000 | -5,88 | 0,80 | -400 | 6.400 | |
2013-01-23 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 7.500 | -6,25 | 1,40 | -702 | 10.531 | |
2013-01-22 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50.000 | 3.323.426 | 1,53 | 27,62 | 1.381.000 | 91.793.026 | |
2013-01-18 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25.000 | 3.273.426 | 0,77 | 26,73 | 668.142 | 87.484.601 | |
2013-01-18 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25.000 | 3.273.426 | 0,77 | 26,73 | 668.142 | 87.484.601 | |
2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 150.000 | 3.223.426 | 4,88 | 26,64 | 3.996.000 | 85.872.069 | |
2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 200.000 | 3.073.426 | 6,96 | 27,66 | 5.531.220 | 84.998.977 | |
2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 125.000 | 2.873.426 | 4,55 | 26,64 | 3.330.000 | 76.548.069 | |
2013-01-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 7.000 | -22,22 | 1,89 | -3.780 | 13.230 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 5.000 | -16,67 | 1,20 | -1.200 | 6.000 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 4.000 | -20,00 | 1,91 | -1.910 | 7.640 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 3.000 | -40,00 | 1,35 | -2.700 | 4.050 | |
2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 1.000 | -50,00 | 2,01 | -2.010 | 2.010 | |
2012-12-13 | 3 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
5.008.400 | ||||||||
2012-12-05 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 20.000 | 2.615.293 | 0,77 | 21,27 | 425.400 | 55.627.282 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 70.000 | 2.565.293 | 2,81 | 21,76 | 1.523.200 | 55.820.776 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 20.000 | 2.495.293 | 0,81 | 20,75 | 415.000 | 51.777.330 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 20.000 | 2.475.293 | 0,81 | 21,01 | 420.200 | 52.005.906 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 10.000 | 2.455.293 | 0,41 | 19,50 | 195.000 | 47.878.214 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 30.000 | 2.445.293 | 1,24 | 21,12 | 633.600 | 51.644.588 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 30.000 | 2.595.293 | 1,17 | 22,71 | 681.300 | 58.939.104 | |
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
CALL OPTION (OBLIGATION TO SELL) |
X - Other | -2.475 | 0 | -100,00 | ||||
2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
X - Other | -247.500 | 2.347.233 | -9,54 | 17,50 | -4.331.250 | 41.076.578 | |
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
2.415.293 | ||||||||
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
133.133 | ||||||||
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
2.594.733 | ||||||||
2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
133.133 | ||||||||
2012-05-15 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 59.500 | 2.862.560 | 2,12 | 7,38 | 439.283 | 21.133.994 | |
2012-05-14 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 25.000 | 2.803.060 | 0,90 | 6,35 | 158.800 | 17.805.037 | |
2012-05-14 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 145.000 | 2.778.060 | 5,51 | 6,35 | 921.040 | 17.646.237 | |
2012-05-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 15.000 | 2.633.060 | 0,57 | 4,82 | 72.300 | 12.691.349 | |
2012-05-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 310.000 | 2.618.060 | 13,43 | 4,82 | 1.493.797 | 12.615.646 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -9.600.000 | 20.580.260 | -31,81 | 0,15 | -1.466.880 | 3.144.664 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -299.570 | 0 | -100,00 | 0,15 | -45.774 | ||
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -400.000 | 299.570 | -57,18 | 0,15 | -61.120 | 45.774 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -1.943.250 | 699.570 | -73,53 | 0,14 | -273.804 | 98.569 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -400.000 | 2.642.820 | -13,15 | 0,16 | -64.560 | 426.551 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -29.740 | 3.042.820 | -0,97 | 0,16 | -4.729 | 483.808 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -2.696.450 | 30.180.260 | -8,20 | 0,15 | -412.018 | 4.611.544 | |
2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -24.681.360 | 32.876.710 | -42,88 | 0,14 | -3.477.604 | 4.632.328 | |
2008-06-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.040 | 3.072.560 | 0,07 | 3,23 | 6.589 | 9.924.369 | |
2008-06-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48.960 | 57.558.070 | 0,09 | 3,23 | 158.141 | 185.912.566 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.340 | 3.070.520 | 0,04 | 3,36 | 4.502 | 10.316.947 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 32.260 | 57.509.110 | 0,06 | 3,36 | 108.394 | 193.230.610 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4.000 | 3.069.180 | 0,13 | 3,43 | 13.720 | 10.527.287 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 96.000 | 57.476.850 | 0,17 | 3,43 | 329.280 | 197.145.596 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 8.000 | 3.065.180 | 0,26 | 3,15 | 25.200 | 9.655.317 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4.000 | 3.057.180 | 0,13 | 3,37 | 13.480 | 10.302.697 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 192.000 | 57.380.850 | 0,34 | 3,15 | 604.800 | 180.749.678 | |
2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinarry Shares |
P - Purchase | 96.000 | 57.188.850 | 0,17 | 3,37 | 323.520 | 192.726.424 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.000 | 3.036.140 | 0,07 | 3,88 | 7.760 | 11.780.223 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48.000 | 56.683.890 | 0,08 | 3,88 | 186.240 | 219.933.493 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4.200 | 3.034.140 | 0,14 | 3,75 | 15.750 | 11.378.025 | |
2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 100.800 | 56.635.890 | 0,18 | 3,75 | 378.000 | 212.384.588 | |
2008-04-16 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 10.000 | 3.015.650 | 0,33 | 3,56 | 35.579 | 10.729.381 | |
2008-04-16 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 90.000 | 56.191.770 | 0,16 | 3,58 | 322.011 | 201.048.534 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.650 | 2.984.350 | 0,22 | 3,12 | 20.749 | 9.311.769 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 156.350 | 55.797.070 | 0,28 | 3,12 | 487.843 | 174.098.018 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.000 | 2.977.700 | 0,40 | 3,32 | 39.856 | 9.889.835 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.780 | 2.965.700 | 0,53 | 3,33 | 52.566 | 9.879.340 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 188.000 | 55.640.720 | 0,34 | 3,32 | 624.404 | 184.799.523 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 247.220 | 55.452.720 | 0,45 | 3,33 | 823.539 | 184.724.101 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 2.949.920 | 0,20 | 3,37 | 20.240 | 9.950.965 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 8.820 | 2.943.920 | 0,30 | 3,38 | 29.814 | 9.951.333 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.000 | 2.935.100 | 0,31 | 3,37 | 30.295 | 9.879.840 | |
2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 17.400 | 2.926.100 | 0,60 | 3,35 | 58.292 | 9.802.728 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 55.205.500 | 0,17 | 3,37 | 317.090 | 186.224.713 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 138.180 | 55.111.500 | 0,25 | 3,38 | 467.090 | 186.293.403 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 272.600 | 54.973.320 | 0,50 | 3,35 | 913.237 | 184.166.119 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 141.000 | 54.700.720 | 0,26 | 3,37 | 474.620 | 184.128.094 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11.900 | 2.908.700 | 0,41 | 3,30 | 39.327 | 9.612.672 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.896.800 | 1,05 | 3,31 | 99.351 | 9.593.333 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 107.100 | 54.559.720 | 0,20 | 3,30 | 353.944 | 180.308.963 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 54.452.620 | 0,87 | 3,31 | 1.556.499 | 180.330.742 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 25.200 | 2.866.800 | 0,89 | 3,28 | 82.568 | 9.393.070 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.841.600 | 1,07 | 3,15 | 94.500 | 8.951.040 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.811.600 | 1,08 | 3,25 | 97.368 | 9.125.329 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 394.800 | 5.398.260 | 7,89 | 3,28 | 1.293.562 | 17.687.399 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 53.587.820 | 0,88 | 3,15 | 1.480.500 | 168.801.633 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 53.117.820 | 0,89 | 3,25 | 1.525.432 | 172.399.197 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 60.000 | 2.781.600 | 2,20 | 3,74 | 224.268 | 10.397.064 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.020 | 2.721.600 | 0,33 | 3,65 | 32.893 | 9.924.859 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 141.440 | 52.647.820 | 0,27 | 3,65 | 515.789 | 191.990.805 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 940.000 | 52.506.380 | 1,82 | 3,74 | 3.513.532 | 196.258.347 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 39.300 | 2.712.580 | 1,47 | 3,86 | 151.824 | 10.479.239 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.600 | 2.673.280 | 0,59 | 3,73 | 58.146 | 9.964.117 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 244.400 | 51.566.380 | 0,48 | 3,73 | 910.952 | 192.203.368 | |
2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 615.700 | 51.321.980 | 1,21 | 3,86 | 2.378.572 | 198.267.073 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 34.200 | 2.657.680 | 1,30 | 3,94 | 134.700 | 10.467.538 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 535.800 | 50.706.280 | 1,07 | 3,94 | 2.110.302 | 199.711.754 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.640 | 2.623.480 | 0,25 | 3,99 | 26.490 | 10.466.111 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18.000 | 2.616.840 | 0,69 | 3,98 | 71.656 | 10.417.378 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282.000 | 50.170.480 | 0,57 | 3,98 | 1.122.614 | 199.723.664 | |
2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 104.060 | 49.888.480 | 0,21 | 3,99 | 415.137 | 199.025.102 | |
2008-02-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.600 | 2.598.840 | 0,25 | 4,01 | 26.484 | 10.428.365 | |
2008-02-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 103.400 | 49.784.420 | 0,21 | 4,01 | 414.913 | 199.769.942 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 3.790 | 2.592.240 | 0,15 | 3,95 | 14.970 | 10.239.348 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 24.000 | 2.588.450 | 0,94 | 3,91 | 93.742 | 10.110.227 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 59.390 | 49.681.020 | 0,12 | 3,95 | 234.590 | 196.240.029 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 376.000 | 49.621.630 | 0,76 | 3,91 | 1.468.618 | 193.817.125 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 46.500 | 2.564.450 | 1,85 | 3,87 | 179.871 | 9.919.805 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 2.517.950 | 0,24 | 3,86 | 23.159 | 9.718.783 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 49.245.630 | 0,19 | 3,86 | 362.821 | 190.078.283 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 728.500 | 49.151.630 | 1,50 | 3,87 | 2.817.984 | 190.128.335 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.000 | 2.511.950 | 0,48 | 3,95 | 47.431 | 9.928.734 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.499.950 | 1,21 | 3,95 | 118.374 | 9.864.303 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 28.380 | 2.469.950 | 1,16 | 3,95 | 112.101 | 9.756.302 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 188.000 | 48.432.130 | 0,39 | 3,95 | 743.089 | 191.432.837 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 48.235.130 | 0,98 | 3,95 | 1.854.526 | 190.326.176 | |
2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 444.620 | 47.765.130 | 0,94 | 3,95 | 1.756.249 | 188.672.264 | |
2008-02-22 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 100 | 2.441.570 | 0,00 | 3,84 | 384 | 9.375.629 | |
2008-02-22 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 900 | 47.320.510 | 0,00 | 3,84 | 3.456 | 181.710.758 | |
2008-02-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 360 | 2.441.470 | 0,01 | 3,81 | 1.371 | 9.297.606 | |
2008-02-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 5.640 | 473.196.910 | 0,00 | 3,81 | 21.478 | 1.802.028.473 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 600 | 3.441.110 | 0,02 | 3,40 | 2.038 | 11.686.010 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 9.400 | 47.313.970 | 0,02 | 3,40 | 31.922 | 160.678.242 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 21.000 | 2.440.510 | 0,87 | 3,71 | 77.914 | 9.054.780 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 120 | 2.419.510 | 0,00 | 3,68 | 442 | 8.903.797 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 329.000 | 47.304.570 | 0,70 | 3,71 | 1.220.656 | 175.509.416 | |
2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 1.880 | 46.975.570 | 0,00 | 3,68 | 6.918 | 172.870.098 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 9.060 | 2.419.390 | 0,38 | 3,79 | 34.314 | 9.163.198 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 6.060 | 2.410.330 | 0,25 | 3,75 | 22.725 | 9.038.738 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 141.940 | 46.973.690 | 0,30 | 3,79 | 537.584 | 177.908.154 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 94.940 | 46.831.750 | 0,20 | 3,75 | 356.025 | 175.619.062 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 8.400 | 2.404.270 | 0,35 | 3,87 | 32.495 | 9.300.678 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 33.000 | 2.320.270 | 1,44 | 3,88 | 128.056 | 9.003.808 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 131.600 | 46.736.810 | 0,28 | 3,87 | 509.081 | 180.796.676 | |
2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 517.000 | 46.605.210 | 1,12 | 3,88 | 2.006.218 | 180.851.517 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.000 | 2.322.870 | 1,84 | 3,69 | 155.022 | 8.573.713 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658.000 | 46.088.210 | 1,45 | 3,69 | 2.428.678 | 170.111.583 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.320.870 | 1,31 | 3,43 | 102.987 | 7.967.315 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 23.640 | 2.290.870 | 1,04 | 3,50 | 82.723 | 8.016.441 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 45.430.210 | 1,05 | 3,43 | 1.613.463 | 155.957.368 | |
2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 370.360 | 44.960.210 | 0,83 | 3,50 | 1.296.001 | 157.329.263 | |
2008-02-01 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.000 | 2.267.230 | 0,67 | 3,23 | 48.456 | 7.324.060 | |
2008-02-01 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235.000 | 44.589.850 | 0,53 | 3,23 | 759.144 | 144.043.051 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 2.252.230 | 0,27 | 3,23 | 19.379 | 7.274.252 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 44.354.850 | 0,21 | 3,23 | 303.601 | 143.257.295 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 600 | 2.246.230 | 0,03 | 3,23 | 1.938 | 7.255.323 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 40.200 | 2.245.630 | 1,82 | 3,21 | 129.203 | 7.217.455 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.400 | 44.260.850 | 0,02 | 3,23 | 30.362 | 142.962.546 | |
2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 629.800 | 44.251.450 | 1,44 | 3,21 | 2.024.177 | 142.224.160 | |
2008-01-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.000 | 2.205.430 | 0,55 | 3,24 | 38.856 | 7.141.182 | |
2008-01-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 188.000 | 43.621.650 | 0,43 | 3,24 | 608.744 | 141.246.903 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.300 | 2.193.430 | 1,97 | 2,99 | 126.477 | 6.558.356 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 13.800 | 2.151.130 | 0,65 | 2,98 | 41.124 | 6.410.367 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 66.270 | 43.433.650 | 0,15 | 2,99 | 198.147 | 129.866.614 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 216.200 | 42.770.950 | 0,51 | 2,98 | 644.276 | 127.457.431 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18.000 | 2.137.330 | 0,85 | 2,88 | 51.908 | 6.163.632 | |
2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282.000 | 42.554.750 | 0,67 | 2,88 | 813.232 | 122.719.388 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 790 | 2.119.330 | 0,04 | 2,90 | 2.293 | 6.151.355 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.520 | 42.272.750 | 0,03 | 2,90 | 36.339 | 122.696.657 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 7.560 | 2.118.540 | 0,36 | 3,16 | 23.888 | 6.694.163 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11.820 | 2.110.980 | 0,56 | 3,13 | 36.994 | 6.606.945 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 118.440 | 42.260.230 | 0,28 | 3,16 | 374.247 | 133.533.875 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 185.180 | 42.141.790 | 0,44 | 3,13 | 579.576 | 131.895.374 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11.460 | 2.099.160 | 0,55 | 3,01 | 34.444 | 6.309.235 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.240 | 2.087.700 | 0,44 | 3,06 | 28.240 | 6.380.638 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 144.760 | 41.956.610 | 0,35 | 3,06 | 442.430 | 128.231.987 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 179.540 | 41.811.850 | 0,43 | 3,01 | 539.625 | 125.669.696 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 27.600 | 2.078.460 | 1,35 | 3,06 | 84.346 | 6.351.774 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180 | 2.008.860 | 0,01 | 3,16 | 568 | 6.341.368 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 432.400 | 41.632.310 | 1,05 | 3,10 | 1.340.440 | 129.060.161 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.820 | 41.199.910 | 0,01 | 3,16 | 8.902 | 130.055.756 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.000 | 2.050.680 | 2,09 | 3,11 | 130.712 | 6.382.126 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.000 | 2.008.680 | 0,75 | 3,06 | 45.909 | 6.147.766 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658.000 | 41.197.090 | 1,62 | 3,11 | 2.047.828 | 128.213.583 | |
2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235.000 | 40.539.090 | 0,58 | 3,06 | 719.241 | 124.073.939 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 27.600 | 2.078.460 | 1,35 | 3,10 | 85.560 | 6.443.226 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180 | 2.050.860 | 0,01 | 3,16 | 568 | 6.473.950 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 432.400 | 41.632.310 | 1,05 | 3,10 | 1.340.440 | 129.060.161 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.820 | 41.199.910 | 0,01 | 3,16 | 8.902 | 130.055.756 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.000 | 2.050.680 | 2,09 | 3,11 | 130.712 | 6.382.126 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.000 | 2.008.680 | 0,75 | 3,06 | 45.909 | 6.147.766 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658.000 | 41.197.090 | 1,62 | 3,11 | 2.047.828 | 128.213.583 | |
2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235.000 | 40.539.000 | 0,58 | 3,06 | 719.241 | 124.073.663 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 22.200 | 1.993.680 | 1,13 | 3,41 | 75.724 | 6.800.442 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 347.800 | 40.304.090 | 0,87 | 3,41 | 1.186.346 | 137.477.251 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 28.320 | 1.971.480 | 1,46 | 3,39 | 96.076 | 6.688.246 | |
2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 443.680 | 39.956.290 | 1,12 | 3,39 | 1.505.184 | 135.551.714 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 69.000 | 1.943.160 | 3,68 | 3,30 | 227.748 | 6.413.788 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.081.000 | 39.521.610 | 2,81 | 3,30 | 3.568.057 | 130.448.978 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 36.000 | 1.874.160 | 1,96 | 3,27 | 117.896 | 6.137.687 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 24.060 | 1.838.160 | 1,33 | 3,30 | 79.283 | 6.057.105 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 564.000 | 37.431.610 | 1,53 | 3,27 | 1.847.044 | 122.584.780 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 376.940 | 37.867.610 | 1,01 | 3,30 | 1.242.093 | 124.781.348 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 1.814.100 | 1,68 | 3,26 | 97.743 | 5.910.519 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 20.000 | 1.784.100 | 1,13 | 2,87 | 57.372 | 5.117.869 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 81.600 | 1.764.100 | 4,85 | 3,11 | 253.401 | 5.478.236 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 1.682.500 | 0,36 | 3,10 | 18.600 | 5.215.750 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.278.400 | 37.020.670 | 3,58 | 3,11 | 3.969.943 | 114.963.989 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 35.742.270 | 0,26 | 3,10 | 291.400 | 110.801.037 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180.000 | 35.648.270 | 0,51 | 2,87 | 516.348 | 102.260.627 | |
2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 37.490.670 | 1,27 | 3,26 | 1.531.307 | 122.148.352 | |
2008-01-04 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.222.000 | 35.045.270 | 3,61 | 2,89 | 3.531.580 | 101.280.830 | |
2008-01-04 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 78.000 | 1.649.500 | 4,96 | 2,89 | 225.420 | 4.767.055 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 69.000 | 1.571.500 | 4,59 | 2,74 | 188.750 | 4.298.838 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.081.000 | 33.823.270 | 3,30 | 2,74 | 2.957.076 | 92.523.555 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48.000 | 1.502.500 | 3,30 | 2,69 | 129.226 | 4.045.030 | |
2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 752.000 | 32.742.270 | 2,35 | 2,69 | 2.024.534 | 88.148.739 | |
2007-12-31 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18.000 | 1.454.500 | 1,25 | 2,60 | 46.717 | 3.775.009 | |
2007-12-31 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282.000 | 31.990.270 | 0,89 | 2,60 | 731.903 | 83.027.547 | |
2007-12-31 | 3/A | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
31.708.270 | ||||||||
2007-12-07 | 3 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
27.876.060 | ||||||||
2007-12-07 | 3 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
1.436.500 | ||||||||
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.315.000 | 209.100 | -86,28 | 4,72 | -6.200.225 | 985.906 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -50.000 | 1.524.100 | -3,18 | 4,55 | -227.500 | 6.934.655 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -30.000 | 1.574.100 | -1,87 | 4,35 | -130.500 | 6.847.335 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -273.550 | 1.604.100 | -14,57 | 4,47 | -1.222.221 | 7.167.119 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.000 | 1.877.650 | 0,11 | 3,98 | 7.960 | 7.473.047 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -2.000 | 1.875.650 | -0,11 | 4,47 | -8.936 | 8.380.404 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -25.000 | 1.877.650 | -1,31 | 4,90 | -122.500 | 9.200.485 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -70.900 | 1.902.650 | -3,59 | 4,47 | -316.781 | 8.501.040 | |
2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -28.550 | 0 | -100,00 | 4,47 | -127.561 | ||
2004-10-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 14.900 | 1.973.550 | 0,76 | 9,87 | 146.991 | 19.469.465 | |
2004-10-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 27.950 | 3,71 | 9,87 | 9.865 | 275.732 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.958.650 | 0,46 | 10,11 | 90.964 | 19.796.271 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 26.950 | 3,85 | 10,11 | 10.107 | 272.386 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.949.650 | 0,46 | 9,90 | 89.112 | 19.304.070 | |
2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 25.950 | 4,01 | 9,90 | 9.901 | 256.939 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 15.800 | 1.940.650 | 0,82 | 9,90 | 156.417 | 19.212.047 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.700 | 24.950 | 7,31 | 9,90 | 16.830 | 247.000 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 13.100 | 1.924.850 | 0,69 | 9,72 | 127.341 | 18.710.889 | |
2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.400 | 23.250 | 6,41 | 9,72 | 13.609 | 226.006 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.400 | 1.911.750 | 1,03 | 9,59 | 186.046 | 18.333.682 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.100 | 21.850 | 10,63 | 9,59 | 20.139 | 209.542 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.892.350 | 0,48 | 8,96 | 80.680 | 16.963.972 | |
2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 19.750 | 5,33 | 8,96 | 8.964 | 177.049 | |
2004-09-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 22.100 | 1.883.350 | 1,19 | 7,69 | 169.843 | 14.473.921 | |
2004-09-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.400 | 18.750 | 14,68 | 7,69 | 18.444 | 144.098 | |
2004-09-15 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 23.400 | 1.861.250 | 1,27 | 7,17 | 167.734 | 13.341.626 | |
2004-09-15 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.500 | 16.350 | 18,05 | 7,17 | 17.920 | 117.198 | |
2004-09-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.300 | 1.837.850 | 0,23 | 6,85 | 29.455 | 12.589.272 | |
2004-09-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 400 | 13.850 | 2,97 | 6,85 | 2.740 | 94.872 | |
2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.833.550 | 0,49 | 6,84 | 61.563 | 12.542.032 | |
2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.824.550 | 0,50 | 6,84 | 61.537 | 12.475.178 | |
2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 13.450 | 8,03 | 6,84 | 6.837 | 91.963 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 700 | 12.450 | 5,96 | 5,84 | 4.091 | 72.765 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.200 | 1.815.550 | 0,34 | 5,84 | 36.237 | 10.611.164 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.500 | 11.750 | 62,07 | 5,83 | 26.214 | 68.447 | |
2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 40.500 | 1.809.350 | 2,29 | 5,83 | 235.925 | 10.540.007 | |
2004-08-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -200 | 7.250 | -2,68 | 5,50 | -1.100 | 39.875 | |
2004-08-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200 | 7.450 | 2,76 | 5,10 | 1.020 | 37.995 | |
2004-08-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.500 | 1.768.850 | 0,14 | 4,75 | 11.875 | 8.402.038 | |
2004-08-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.300 | 7.250 | 46,46 | 4,72 | 10.850 | 34.202 | |
2004-08-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 21.300 | 1.766.350 | 1,22 | 4,72 | 100.483 | 8.332.756 | |
2004-07-21 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.800 | 4.950 | 130,23 | 5,67 | 15.889 | 28.090 | |
2004-07-21 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 25.652 | 1.745.050 | 1,49 | 5,67 | 145.567 | 9.902.635 | |
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.400 | 2.150 | 186,67 | 5,89 | 8.242 | 12.657 | |
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.648 | 1.719.398 | 0,74 | 5,89 | 74.468 | 10.123.300 | |
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 750 | 750 | 5,96 | 4.472 | 4.472 | ||
2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.750 | 1.706.750 | 0,40 | 5,96 | 40.252 | 10.177.862 | |
2004-05-18 |
|
4/A | BPA |
BIOSANTE PHARMACEUTICALS INC
Warrants |
P - Purchase | 97.500 | 97.500 | |||||
2004-05-18 |
|
4/A | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 650.000 | 1.700.000 | 61,90 | 6,00 | 3.900.000 | 10.200.000 | |
2004-05-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 650.000 | 1.700.000 | 61,90 | 6,00 | 3.900.000 | 10.200.000 | |
2004-02-12 | 3 | ANTR.OB |
ANTARES PHARMA INC
Common Stock, $0.01 par value per share |
2.700.000 | ||||||||
2004-02-05 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -87.400 | 1.050.000 | -7,68 | 6,44 | -562.576 | 6.758.640 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -35.000 | 1.137.400 | -2,99 | 5,62 | -196.700 | 6.392.188 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 1.172.400 | -7,86 | 5,68 | -568.000 | 6.659.232 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -5.000 | 1.272.400 | -0,39 | 5,65 | -28.250 | 7.189.060 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -15.000 | 1.277.400 | -1,16 | 5,84 | -87.600 | 7.460.016 | |
2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 1.292.400 | -7,18 | 5,66 | -566.000 | 7.314.984 | |
2003-08-13 | 3 | BISP.OB |
BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 |
225.000 | ||||||||
2003-08-13 | 3 | BISP.OB |
BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 |
1.392.400 |